M&A Deal Summary

Arbutus Biopharma Acquires Protiva Biotherapeutics

On May 30, 2008, Arbutus Biopharma acquired medical products company Protiva Biotherapeutics

Acquisition Highlights
  • This is Arbutus Biopharma’s 1st transaction in the Medical Products sector.
  • This is Arbutus Biopharma’s 1st transaction in Canada.
  • This is Arbutus Biopharma’s 1st transaction in British Columbia.

M&A Deal Summary
Date 2008-05-30
Target Protiva Biotherapeutics
Sector Medical Products
Buyer(s) Arbutus Biopharma
Deal Type Add-on Acquisition

Target

Protiva Biotherapeutics

Burnaby, British Columbia, Canada
Protiva Biotherapeutics, Inc. is a biotechnology company, develops nucleic acid based pharmaceutical products.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Arbutus Biopharma

Warminster, Pennsylvania, United States
Category Company
Sector Life Science
Employees73
Revenue 18M USD (2023)
DESCRIPTION

Arbutus Biopharma is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). Arbutus Biopharma is based in Warminster, Pennsylvania.

DEAL STATS #
Overall 1 of 2
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2008) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-03-04 OnCore Biopharma

Doylestown, Pennsylvania, United States

OnCore Biopharma, Inc. is a biopharmaceutical company provides research, development, and commercialization of therapies.

Buy -
Mergr

Product

Company

Legal